ECO-4601: Additional Phase I/II data

Additional data from the open-label, Canadian Phase I/II ECO-4601-101 trial in 26 advanced cancer patients showed that IV ECO-4601 was safe and well tolerated at daily doses of up to 480 mg/m 2. Six o...